enVVeno MedicalNVNO +16.14%26 ROA % is -55.32% as of Mar. 2026. GuruFocus rates NVNO with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, enVVeno Medical ranks worse than 86.93% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. enVVeno Medical's annualizedNet Income for the quarter that ended in Mar. 2026 was $-15.40 Mil.
enVVeno Medical's average Total Assets over the quarter that ended in Mar. 2026 was $27.83 Mil. Therefore, enVVeno Medical's annualized ROA % for the quarter that ended in Mar. 2026 was -55.32%.
The historical rank and industry rank for enVVeno Medical's ROA % or its related term are showing as below:
NVNO'
s ROA % Range Over the Past 10 Years
Min: -451.78 Med: -91.51 Max: -46.63
Current: -56.97
During the past 11 years, enVVeno Medical's highest ROA % was -46.63%. The lowest was -451.78%. And the median was -91.51%.
NVNO's ROA % is ranked worse than 86.93% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs NVNO: -56.97
enVVeno Medical (NAS:NVNO) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
enVVeno Medical ROA % Related Terms
enVVeno Medical ROA % Historical Data
* Premium members only.
The historical data trend for enVVeno Medical's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, enVVeno Medical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's ROA % distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
enVVeno Medical (NVNO) has a ROA % of -55.32% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on enVVeno Medical and its competitors. According to the industry distribution chart, enVVeno Medical ranks #745 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 86.9%.
Is enVVeno Medical's ROA % too high?
enVVeno Medical's current ROA % is -55.32%. Based on the distribution chart, enVVeno Medical ranks #745 out of 857 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, enVVeno Medical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's ROA % compare to BMRA and STME?
According to the Medical Devices & Instruments industry distribution chart, enVVeno Medical ranks #745 out of 857 companies for ROA %. This places enVVeno Medical in the lower half of its industry. The industry median ROA % is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on enVVeno Medical and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enVVeno Medical's current ROA % is -55.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current ROA % of -55.32%. The current ROA % is -55.32%. enVVeno Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current ROA % is -55.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
26GF Score
Get the complete analysis for NVNO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNO has been successfully added to your 
